Multiple sclerosis and immune system biomarkers: Novel
comparison in glatiramer acetate and interferon beta-1a-treated
patient groups

J 2021

Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups

PAVELEK, Zbysek, Michal NOVOTNY, Ondrej SOUCEK, Jan KREJSEK, Lukas SOBISEK et. al.

Základní údaje

Originální název

Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups

Autoři

PAVELEK, Zbysek (203 Česká republika, garant), Michal NOVOTNY (203 Česká republika), Ondrej SOUCEK (203 Česká republika), Jan KREJSEK (203 Česká republika), Lukas SOBISEK (203 Česká republika), Ilona SEJKOROVA (203 Česká republika), Jiri MASOPUST (203 Česká republika), Kamil KUCA (203 Česká republika), Martin VALIS (203 Česká republika), Blanka KLIMOVA (203 Česká republika) a Pavel ŠTOURAČ (203 Česká republika, domácí)

Vydání

MULTIPLE SCLEROSIS AND RELATED DISORDERS, OXFORD, ELSEVIER SCI LTD, 2021, 2211-0348

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.808

Kód RIV

RIV/00216224:14110/21:00123212

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.msard.2021.103082

UT WoS

000687405500004

Klíčová slova anglicky

Multiple sclerosis; BAFF; IL-10; Mx1; IgG; Glatiramer acetate; Interferon beta-1a

Štítky

14110221, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 12. 2021 14:44, Mgr. Tereza Miškechová

Anotace

V originále

Background: Multiple sclerosis (MS) is a chronic, demyelinating disease of the central nervous system (CNS). T cells and B lymphocytes are involved in the development of this disease. Methods: The following biomarkers were determined in peripheral blood in 28 patients treated with glatiramer acetate (GA) and 21 patients treated with interferon beta 1-a (IFN): IL-10, BAFF, Mx1, IgG, IgG1, IgG2, IgG3 and IgG4 (at baseline and after 6 months of treatment). All participants had confirmed MS diagnosis. Objectives: The primary objective is to assess a percentual change of biomarkers after 6 months since the first-line treatment initiation with GA or IFN. The secondary objective is to explore correlations between the baseline biomarkers' values (levels). Results: A positive trend was observed in the increase in IL-10 concentration by 30.33 % (IFN) and by 15.65 % (GA). In the IFN group, we observed a statistically significant increase in the BAFF protein concentration by 29.9% (P < 0.001). We found that Mx1 protein levels did not change with the administration of GA, which can be explained by the different mechanisms of action of GA. The serum levels of IgG immunoglobulins and both IgG1 and IgG4 subclasses in both groups of patients were increased. Thus, our data were in accordance with the generally accepted assumption that both IFN and GA are capable of modulating the B cell system. Conclusions: Our results suggest that treatment with IFN and GA has a more pronounced influence on the B cell system of MS.

Citovat

PAVELEK, Zbysek, Michal NOVOTNY, Ondrej SOUCEK, Jan KREJSEK, Lukas SOBISEK, Ilona SEJKOROVA, Jiri MASOPUST, Kamil KUCA, Martin VALIS, Blanka KLIMOVA a Pavel ŠTOURAČ. Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups. MULTIPLE SCLEROSIS AND RELATED DISORDERS. OXFORD: ELSEVIER SCI LTD, 2021, roč. 53, August 2021, s. 1-7. ISSN 2211-0348. Dostupné z: https://dx.doi.org/10.1016/j.msard.2021.103082.

@article{1808669,
   author = {Pavelek, Zbysek and Novotny, Michal and Soucek, Ondrej and Krejsek, Jan and Sobisek, Lukas and Sejkorova, Ilona and Masopust, Jiri and Kuca, Kamil and Valis, Martin and Klimova, Blanka and Štourač, Pavel},
   article_location = {OXFORD},
   article_number = {August 2021},
   doi = {http://dx.doi.org/10.1016/j.msard.2021.103082},
   keywords = {Multiple sclerosis; BAFF; IL-10; Mx1; IgG; Glatiramer acetate; Interferon beta-1a},
   language = {eng},
   issn = {2211-0348},
   journal = {MULTIPLE SCLEROSIS AND RELATED DISORDERS},
   title = {Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups},
   url = {https://www.sciencedirect.com/science/article/pii/S2211034821003497?via%3Dihub},
   volume = {53},
   year = {2021}
}

TY  - JOUR
ID  - 1808669
AU  - Pavelek, Zbysek - Novotny, Michal - Soucek, Ondrej - Krejsek, Jan - Sobisek, Lukas - Sejkorova, Ilona - Masopust, Jiri - Kuca, Kamil - Valis, Martin - Klimova, Blanka - Štourač, Pavel
PY  - 2021
TI  - Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups
JF  - MULTIPLE SCLEROSIS AND RELATED DISORDERS
VL  - 53
IS  - August 2021
SP  - 1-7
EP  - 1-7
PB  - ELSEVIER SCI LTD
SN  - 22110348
KW  - Multiple sclerosis
KW  - BAFF
KW  - IL-10
KW  - Mx1
KW  - IgG
KW  - Glatiramer acetate
KW  - Interferon beta-1a
UR  - https://www.sciencedirect.com/science/article/pii/S2211034821003497?via%3Dihub
N2  - Background: Multiple sclerosis (MS) is a chronic, demyelinating disease of the central nervous system (CNS). T cells and B lymphocytes are involved in the development of this disease. Methods: The following biomarkers were determined in peripheral blood in 28 patients treated with glatiramer acetate (GA) and 21 patients treated with interferon beta 1-a (IFN): IL-10, BAFF, Mx1, IgG, IgG1, IgG2, IgG3 and IgG4 (at baseline and after 6 months of treatment). All participants had confirmed MS diagnosis. Objectives: The primary objective is to assess a percentual change of biomarkers after 6 months since the first-line treatment initiation with GA or IFN. The secondary objective is to explore correlations between the baseline biomarkers' values (levels). Results: A positive trend was observed in the increase in IL-10 concentration by 30.33 % (IFN) and by 15.65 % (GA). In the IFN group, we observed a statistically significant increase in the BAFF protein concentration by 29.9% (P < 0.001). We found that Mx1 protein levels did not change with the administration of GA, which can be explained by the different mechanisms of action of GA. The serum levels of IgG immunoglobulins and both IgG1 and IgG4 subclasses in both groups of patients were increased. Thus, our data were in accordance with the generally accepted assumption that both IFN and GA are capable of modulating the B cell system. Conclusions: Our results suggest that treatment with IFN and GA has a more pronounced influence on the B cell system of MS.
ER  -

PAVELEK, Zbysek, Michal NOVOTNY, Ondrej SOUCEK, Jan KREJSEK, Lukas SOBISEK, Ilona SEJKOROVA, Jiri MASOPUST, Kamil KUCA, Martin VALIS, Blanka KLIMOVA a Pavel ŠTOURAČ. Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups. \textit{MULTIPLE SCLEROSIS AND RELATED DISORDERS}. OXFORD: ELSEVIER SCI LTD, 2021, roč.~53, August 2021, s.~1-7. ISSN~2211-0348. Dostupné z: https://dx.doi.org/10.1016/j.msard.2021.103082.

Podrobný výpis o publikaci